Semax Peptide: Neuroprotective ACTH Analog Guide

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (molecular formula C37H51N9O10S, molecular weight 813.9 g/mol). It consists of the ACTH(4-7) fragment, the four-amino-acid core responsible for the nootropic activity of adrenocorticotropic hormone, fused with the stabilizing tripeptide Pro-Gly-Pro at the C-terminus. Developed in the early 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been approved as a prescription pharmaceutical in Russia and was formally added to the Russian List of Vital and Essential Drugs (ZHVLP) on December 7, 2011.

Primary areas of research and clinical use include:

• Ischemic stroke recovery and neuroprotection
• Cognitive disorders including memory impairment and encephalopathy
• Optic nerve diseases including glaucomatous neuropathy
• Attention-deficit/hyperactivity disorder (preliminary)
• Immune modulation

What Is Semax?

Semax was created in 1982 by a research team led by academicians Nikolai Myasoedov and Igor Ashmarin at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Their work built on decades of research showing that ACTH fragments, particularly the 4-7 and 4-10 residue sequences, possessed potent nootropic and neurotrophic activity independent of the adrenal hormonal effects associated with full-length ACTH. The challenge was that these short peptide fragments degraded rapidly in biological systems, lasting only minutes in plasma before enzymatic cleavage rendered them inactive.

The solution was the addition of Pro-Gly-Pro to the C-terminus of the ACTH(4-7) fragment. This tripeptide is itself a fragment of proline-rich peptides involved in immune regulation, and its attachment dramatically extended the biological half-life of the core sequence while contributing independent anti-inflammatory properties. The resulting compound, Semax, retained the nootropic and neurotrophic effects of the ACTH fragment while resisting enzymatic degradation long enough for clinical utility through intranasal administration.

Semax was initially pursued as a treatment for stroke patients suffering ischemic brain damage. Over more than a decade of preclinical and clinical study in Russia, its indications expanded. The Russian Federation approved Semax in two formulations: a 0.1% intranasal solution for cognitive enhancement, memory disorders, and general neuroprotection, and a 1% intranasal solution for acute neurological conditions including ischemic stroke and optic nerve disease. It was formally added to the Russian List of Vital and Essential Drugs on December 7, 2011.

Critically, Semax is devoid of hormonal activity. Despite its derivation from ACTH, the heptapeptide does not stimulate adrenal cortisol release or engage the hypothalamic-pituitary-adrenal axis. Its biological activity is confined to neurotrophic, neuroprotective, and immunomodulatory pathways, a deliberate design outcome that distinguishes it from its parent hormone.

How It Works

Semax acts through multiple converging mechanisms that collectively support neuronal survival, synaptic plasticity, and neurotransmitter balance. The breadth of its pharmacological profile reflects the multifunctionality of melanocortin-derived peptides, which interact with diverse receptor systems and intracellular signaling cascades.

BDNF and Neurotrophic Factor Upregulation

The most extensively documented mechanism of Semax is its potent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Intranasal administration of Semax significantly increases BDNF mRNA expression in the rat hippocampus and frontal cortex within 30 to 90 minutes, with effects persisting for several hours.

This upregulation occurs through activation of the cAMP response element-binding protein (CREB) pathway. CREB is a transcription factor that, when phosphorylated, drives expression of neurotrophin genes including BDNF and NGF. The resulting increase in BDNF levels activates the tropomyosin receptor kinase B (TrkB) receptor, initiating downstream signaling cascades through the MAPK/ERK, PI3K/Akt, and PLCgamma pathways. These cascades promote synaptic strengthening, dendritic branching, neurogenesis, and long-term potentiation, the cellular substrate of learning and memory.

In cerebral ischemia models, Semax treatment promoted earlier upregulation of BDNF, TrkC, and TrkA genes while preventing the ischemia-induced decline in NT-3 and NGF transcription. This neurotrophic rescue effect is a primary mechanism underlying Semax's neuroprotective properties in stroke.

Dopaminergic and Serotonergic Modulation

Semax modulates both dopaminergic and serotonergic neurotransmission, though its effects are more modulatory than directly stimulatory. For users exploring Semax alongside immune-focused peptides, Thymosin Alpha 1 is a commonly combined option given its complementary immunomodulatory profile. Studies using in vivo microdialysis in rodents demonstrated that Semax alone did not significantly alter basal dopamine or serotonin concentrations in the striatum. However, serotonin metabolite (5-HIAA) levels gradually increased to approximately 180% of baseline within one to four hours after Semax administration, indicating enhanced serotonergic turnover.

The more striking finding involved dopamine modulation under stimulated conditions: when Semax was administered 20 minutes prior to d-amphetamine, it dramatically enhanced the amphetamine-induced increase in extracellular dopamine levels and locomotor activity. This suggests Semax sensitizes or primes dopaminergic neurons without directly flooding the synapse with dopamine, a pharmacological profile more consistent with adaptive enhancement than with stimulant-like activity.

This dual neurotransmitter modulation likely contributes to the subjective improvements in focus, motivation, and mood stability reported with Semax use, and provides a mechanistic rationale for its investigation in attention-deficit conditions. Semax is one of the top-ranked options in the best peptides for cognitive enhancement guide.

Neuroprotective Mechanisms

In models of cerebral ischemia-reperfusion, Semax exerts broad neuroprotective effects at both the genomic and proteomic levels. Genome-wide transcriptional analysis following experimental stroke in rats revealed that Semax significantly altered the expression of genes related to immune, vascular, and neurotransmitter systems.

At the protein level, 24 hours after transient middle cerebral artery occlusion, Semax treatment resulted in upregulation of active CREB in subcortical structures, downregulation of matrix metalloproteinase-9 (MMP-9) in the adjacent frontoparietal cortex, and downregulation of active JNK (c-Jun N-terminal kinase) in both tissues. MMP-9 downregulation is particularly significant because MMP-9 contributes to blood-brain barrier breakdown after ischemia, and JNK is a key mediator of apoptotic cell death pathways. Semax also binds copper(II) ions with high affinity, which may contribute antioxidant effects by preventing copper-catalyzed oxidative damage in ischemic tissue.

Immune and Anti-Inflammatory Effects

Semax suppresses the transcription of major pro-inflammatory mediators induced by ischemia-reperfusion, including Il1a, Il1b, Il6, Ccl3, and Cxcl2. This anti-inflammatory action compensates for the surge of inflammatory cytokines that occurs following ischemic injury and contributes to reduced secondary brain damage.

Simultaneously, Semax enhances aspects of adaptive immunity. It activates antigen presentation signaling pathways, intensifies interferon signaling, and affects immunoglobulin synthesis. Immunobiochemical analysis of cerebrospinal fluid in stroke patients receiving Semax demonstrated a shift in neuromodulatory balance toward anti-inflammatory agents (interleukin-10, transforming growth factor-beta) and away from pro-inflammatory factors (interleukin-8, C-reactive protein).

Under chronic social stress conditions, Semax also modulated levels of IL-1beta, IL-4, IL-6, TNF-alpha, and TGF-beta1, suggesting immunomodulatory activity that extends beyond acute ischemic contexts.

Variants

Semax has spawned two major structural variants designed to improve upon its already favorable pharmacological profile through targeted chemical modifications.

N-Acetyl Semax (NA-Semax)

N-Acetyl Semax features an acetyl group attached to the N-terminus of the peptide. This modification shields the methionine residue from aminopeptidase-mediated degradation, resulting in enhanced enzymatic stability. Standard Semax has a plasma half-life of approximately 3–5 minutes; the "2–4 hours" sometimes cited in community discussions reflects the downstream duration of BDNF and neurotrophin effects, not actual plasma persistence. N-Acetyl Semax extends plasma half-life and demonstrates a longer duration of downstream neurotrophin effects (approximately 6 to 12 hours) and improved blood-brain barrier penetration. Dosing is typically 30 to 40% lower than standard Semax due to increased bioavailability. 400 mcg of N-Acetyl Semax is roughly equivalent to 600 mcg of standard Semax.

N-Acetyl Semax Amidate (NASA)

N-Acetyl Semax Amidate combines both N-terminal acetylation and C-terminal amidation, protecting both ends of the peptide from enzymatic attack. This dual modification confers the greatest stability in blood plasma and brain tissue of any Semax variant, with a plasma half-life of approximately 30 minutes (compared to approximately 3–5 minutes for standard Semax). The "6–12 hours" sometimes attributed to this variant reflects downstream neurotrophin and neurotransmitter effects, not plasma presence. It is considered the most potent version in terms of bioavailability per microgram administered and is used at correspondingly lower doses than both standard Semax and N-Acetyl Semax.

Research Evidence

Semax has accumulated a substantial body of research, though the majority originates from Russian institutions and journals. The evidence base spans genome-wide transcriptomic analyses, proteomic studies, rodent behavioral models, and human clinical trials.

Ischemic Stroke

The most robust clinical evidence for Semax involves ischemic stroke treatment. A clinical study by Gusev et al. (2018) of 110 stroke patients demonstrated that Semax administration increased plasma BDNF levels that remained elevated throughout the study period, accelerated functional recovery, and improved motor performance. Inclusion of Semax in combined intensive therapy during acute ischemic stroke increased the rate of neurological function restoration, with particular benefit for motor disorders and general cerebral symptoms.

Mechanistic studies using transcriptomic analysis revealed that Semax suppresses pro-inflammatory gene expression and activates neurotransmission-related genes following ischemia-reperfusion. At the protein level, Semax modulated key players in ischemic damage including CREB, MMP-9, c-Fos, and JNK, establishing a clear molecular basis for the observed clinical effects.

Cognitive Enhancement

Semax was originally developed as a nootropic, and multiple Russian studies have documented improvements in attention, memory, and learning in both healthy volunteers and patients with cognitive decline. The BDNF and NGF upregulation demonstrated in animal models provides a mechanistic explanation for these effects. A 15-year research summary published by members of the original development team documented consistent nootropic efficacy across multiple trial designs.

Optic Nerve Disease

Clinical studies in patients with glaucomatous optic neuropathy demonstrated that intranasal Semax improved visual function parameters beyond what was achieved with standard neuroprotective treatment. Electrophysiological assessments confirmed structural benefits. The peptide's ability to penetrate to retinal tissue after intranasal administration, combined with local BDNF and NGF upregulation, provides the mechanistic basis for these ophthalmic applications.

ADHD

A published hypothesis paper proposed Semax as a treatment candidate for ADHD based on its dopamine-augmenting and BDNF-stimulating properties. A small pilot study in children with ADHD reported improvements in attention and reduced impulsivity. Animal models have shown that Semax modulates cortical metabotropic glutamate receptors (mGluR II) in attention-deficit paradigms. This remains a preliminary area of investigation without large-scale controlled trials.

Alzheimer's Disease Model

Recent research demonstrated that Semax and its derivative improved cognitive functions in mice in an amyloid-beta-induced Alzheimer's disease model, suggesting potential applications in neurodegenerative conditions beyond acute ischemic injury.

Stacking

Semax's multifactorial mechanism of action makes it a logical candidate for combination with compounds that address complementary neurological pathways.

Semax + Selank

The most commonly discussed pairing. Semax provides dopaminergic activation, BDNF upregulation, and cognitive drive; Selank adds GABAergic modulation and anxiolysis. See Selank vs Semax for a detailed comparison of both peptides. Both are intranasal peptides with compatible administration routes and timing. The combination aims to enhance cognition and motivation while maintaining calm focus, stimulation without agitation. Both are approved medications in Russia, though no formal combination trials have been published.

Semax + Noopept

Noopept is a synthetic dipeptide nootropic that also enhances BDNF and NGF levels. The combination is popular in nootropic communities for synergistic neurotrophic stimulation. Mechanistically, the overlap in BDNF pathways raises theoretical concerns about excessive neurotrophin signaling, though no adverse interactions have been reported.

Semax + Racetams

Some users combine Semax with piracetam or other racetam-class nootropics. The rationale is that racetams modulate AMPA and acetylcholine receptor systems while Semax works through neurotrophin and monoamine pathways. These are non-overlapping mechanisms that could produce additive cognitive benefits.

General Stacking Caution: Formal interaction studies do not exist for any Semax combinations. Given Semax's effects on dopaminergic and serotonergic systems, particular caution is warranted when combining it with SSRIs, MAOIs, stimulants, or other serotonergic/dopaminergic drugs. Establishing individual response to Semax alone before adding compounds is essential.

Side Effects

Semax has demonstrated a favorable safety profile across both published research and decades of clinical use in Russia. No serious adverse events have been reported in published clinical or preclinical studies.

Commonly Reported:

• Nasal irritation, burning sensation, or mild congestion (localized to the administration route)
• Headache (typically mild, may relate to initial neurotransmitter modulation)
• Sleep disturbance or insomnia (when administered too late in the day)

Less Commonly Reported:

• Transient anxiety or restlessness (more common at higher doses; paradoxical given Semax's general anxiolytic trend)
• Nausea
• Dizziness
• Minor blood pressure fluctuations

Drug Interactions: Semax affects both dopaminergic and serotonergic systems. Combining it with SSRIs, SNRIs, MAOIs, antipsychotics, or stimulant medications could produce amplified or unpredictable effects. No formal interaction studies exist, so co-administration with psychoactive drugs should proceed with caution and medical oversight.

Unstudied Populations: Safety has not been evaluated in pregnancy, lactation, or in patients with significant hepatic or renal impairment. Long-term safety data in healthy populations using research-grade material remains limited.

Sourcing Risks: As with all research peptides obtained outside regulated pharmaceutical supply chains, contamination and purity risks are separate from the compound's intrinsic safety profile. Independent third-party testing is advisable for any research-grade Semax product.

Legal Status / FDA

Semax occupies a split regulatory landscape. Fully approved in one national system, entirely unregulated in most others.

Russia and CIS Countries:

• Listed on the Russian List of Vital and Essential Drugs since December 7, 2011
• Approved for ischemic stroke, transient ischemic attack, cognitive disorders, encephalopathy, and optic nerve atrophy
• Available as a prescription medication in two formulations (0.1% and 1% intranasal solutions)
• Also reportedly available in Ukraine, though formal regulatory documentation is limited

United States:

• Not FDA-approved for any indication
• Has not undergone FDA clinical trials or new drug application review
• Cannot legally be marketed as a drug, food, or dietary supplement for human consumption
• Exists in a regulatory gray area as a research chemical when sold without therapeutic claims
• Not DEA-scheduled; possession is not a controlled substance offense

European Union, United Kingdom, Australia:

• Not approved by EMA, MHRA, or TGA
• Available as a research chemical in most jurisdictions
• Regulatory classification varies by country

Sports / WADA

Semax is not explicitly named on the World Anti-Doping Agency Prohibited List. However, it almost certainly falls under the S0 category (Non-Approved Substances), which prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use.

Although Semax is approved in Russia, the WADA S0 category has historically been interpreted to refer to substances lacking approval from major regulatory authorities (FDA, EMA, TGA). Athletes subject to anti-doping testing should treat Semax as prohibited. Its neuroprotective and cognitive-enhancing properties, combined with its dopamine-modulating effects, make it a plausible target for future explicit listing.

Key considerations for athletes:

• S0 classification means Semax is prohibited both in-competition and out-of-competition
• Detection methods for peptides continue to improve; absence of a current test does not mean safety from detection
• Individual sports organizations may impose additional restrictions
• Athletes should consult their relevant anti-doping authority before any use

Conclusion

Semax is one of the more scientifically substantiated nootropic peptides available, supported by a body of research that includes genome-wide transcriptomic analyses, proteomic studies, and human clinical trials in stroke and cognitive disorders. Its development at the Institute of Molecular Genetics over more than four decades, its formal approval as a prescription pharmaceutical in Russia, and its listing as a Vital and Essential Drug all distinguish it from the majority of peptides circulating in the biohacking and research chemical markets.

The molecular evidence is genuinely compelling: Semax upregulates BDNF and NGF through clearly defined CREB-mediated pathways, modulates dopaminergic and serotonergic neurotransmission through sensitization rather than brute-force stimulation, suppresses neuroinflammatory cascades at the transcriptomic level during ischemic injury, and exerts immunomodulatory effects that extend to adaptive immunity. These are not speculative mechanisms. They have been demonstrated across multiple independent studies using genomic, proteomic, and biochemical methodologies.

The primary limitation is the geographic concentration of the clinical evidence. The vast majority of human studies were conducted in Russia, many published only in Russian-language journals, and none have been replicated in large-scale Western clinical trials. This does not invalidate the evidence, but it does limit the ability to assess it by the standards that Western regulatory agencies require. For individuals using Semax outside the Russian healthcare system, the familiar caveats apply: research-grade sourcing carries contamination risk, approved dosing protocols may not translate directly to self-experimentation contexts, and long-term safety data in healthy populations remains sparse.

Within those constraints, Semax represents a peptide with a real mechanistic foundation, real clinical history, and a safety record that, across decades of use in Russia and years of community use elsewhere, has not produced any serious safety signals. For nootropic and neuroprotective applications, it remains one of the better-supported options available.